GlassScriptPhysician profile
Winston B Morris
NPI 1295791184
$8,849.74
in general payments reported to CMS, 2019-2025
42 companies · $204 in 2025
The $204 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,152 · 2020: $1,100 · 2021: $2,253 · 2022: $2,265 · 2023: $1,378 · 2024: $498 · 2025: $204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,080.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,079.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,528.69 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,176.90 | 2019-2025 | Farxiga, Airsupra, Evusheld |
| Glaxosmithkline, LLC. | $876.65 | 2019-2023 | Trelegy Ellipta |
| Abbvie INC. | $694.19 | 2020-2023 | |
| Lilly USA, LLC | $657.28 | 2019-2023 | Mounjaro, Trulicity, Jardiance |
| Abbott Laboratories | $371.17 | 2019-2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $343.05 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $308.01 | 2019-2023 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $264.43 | 2019-2023 | Jardiance |
| Eisai INC. | $228.84 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $218.65 | 2019-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $216.46 | 2021-2023 | |
| Biohaven Pharmaceuticals, INC. | $188.92 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $156.99 | 2022 | |
| Amgen INC. | $147.38 | 2019-2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Winston Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.